{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:45:11Z","timestamp":1787165111807,"version":"build-2736575974"},"reference-count":128,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006049","name":"Comisi\u00f3n Sectorial de Investigaci\u00f3n Cient\u00edfica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000646","name":"Japan Society for the Promotion of Science London","doi-asserted-by":"publisher","award":["24K10929"],"award-info":[{"award-number":["24K10929"]}],"id":[{"id":"10.13039\/501100000646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["PID2024-157753OB-C21"],"award-info":[{"award-number":["PID2024-157753OB-C21"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["PID2021\\u2010124247OB\\u2010C21"],"award-info":[{"award-number":["PID2021\\u2010124247OB\\u2010C21"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009042","name":"Universidad de Sevilla","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"State Agency of Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejmech.2025.118500","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T16:10:47Z","timestamp":1765901447000},"page":"118500","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Neutral sp2-iminosugars exploiting non-glycone interactions for selective acid \u03b1- and \u03b2-glucosidase activity modulation: Pharmacological chaperones for Gaucher and Pompe diseases"],"prefix":"10.1016","volume":"304","author":[{"given":"M. Isabel","family":"Garc\u00eda-Moreno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoko","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Nanba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Garc\u00eda Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumi","family":"Higaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7676-7721","authenticated-orcid":false,"given":"Carmen","family":"Ortiz Mellet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118500_bib1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-018-0025-4","article-title":"Lysosomal storage diseases","volume":"4","author":"Platt","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ejmech.2025.118500_bib2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2025.118500_bib3","series-title":"The Metabolic and Molecular Basis of Inherited Disease","first-page":"3389","article-title":"Glycogen storage disease type II: acid alphaglucosidase (acid maltase) deficiency","author":"Hirschhorn","year":"2001"},{"key":"10.1016\/j.ejmech.2025.118500_bib4","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe's disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2025.118500_bib5","doi-asserted-by":"crossref","first-page":"D571","DOI":"10.1093\/nar\/gkab1045","article-title":"The carbohydrate-active enzyme database: functions and literature","volume":"50","author":"Drula","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2025.118500_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2024.108590","article-title":"Pompe disease: unmet needs and emerging therapies","volume":"143","author":"George","year":"2024","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.ejmech.2025.118500_bib7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.neuroscience.2024.09.043","article-title":"Global birth prevalence of Pompe disease: a systematic review and meta-analysis","volume":"563","author":"Kong","year":"2024","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejmech.2025.118500_bib8","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","article-title":"Phenotype, diagnosis, and treatment of Gaucher's disease","volume":"372","author":"Grabowski","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2025.118500_bib9","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3390\/jcm9030736","article-title":"Glucocerebrosidase: functions in and beyond the lysosome","volume":"9","author":"Boer","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejmech.2025.118500_bib10","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/humu.20676","article-title":"Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)","volume":"29","author":"Hruska","year":"2008","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ejmech.2025.118500_bib11","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41582-024-00999-z","article-title":"Gaucher disease provides a unique window into Parkinson disease pathogenesis","volume":"20","author":"Hertz","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejmech.2025.118500_bib12","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2406009121","article-title":"High-throughput screening for small-molecule stabilizers of misfolded glucocerebrosidase in Gaucher disease and Parkinson's disease","volume":"121","author":"Williams","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2025.118500_bib13","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease","volume":"361","author":"Sidransky","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118500_bib14","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1146\/annurev.med.57.110104.115650","article-title":"Enzyme replacement for lysosomal diseases","volume":"57","author":"Brady","year":"2006","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ejmech.2025.118500_bib15","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1474-4422(24)00518-0","article-title":"Clinical insights in enzyme replacement therapy for metabolic storage disorders: lessons from Pompe disease","volume":"24","author":"van der Beek","year":"2025","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejmech.2025.118500_bib16","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease","volume":"324","author":"Barton","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118500_bib17","doi-asserted-by":"crossref","first-page":"842","DOI":"10.3390\/jcm14030842","article-title":"Home enzyme replacement therapy in gaucher disease: a review","volume":"14","author":"Kie\u0107-Wilk","year":"2025","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejmech.2025.118500_bib18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11940-017-0481-2","article-title":"Current and future treatments for lysosomal storage disorders","volume":"19","author":"Rastall","year":"2017","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.ejmech.2025.118500_bib19","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1039\/D4MA00943F","article-title":"Virus-based enzymatic nanoreactors with acid alpha-glucosidase for the potential treatment of Pompe disease","author":"Molina-Sol\u00eds","year":"2025","journal-title":"Mater. Adv."},{"key":"10.1016\/j.ejmech.2025.118500_bib20","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s10545-006-0272-5","article-title":"Substrate reduction therapy of glycosphingolipid storage disorders","volume":"19","author":"Aerts","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ejmech.2025.118500_bib21","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1001\/jama.2015.459","article-title":"Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial","volume":"313","author":"Mistry","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2025.118500_bib22","article-title":"Small-molecule inhibition of glycogen synthase 1 for the treatment of Pompe disease and other glycogen storage disorders","volume":"1","author":"Ullman","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2025.118500_bib23","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ymthe.2024.11.033","article-title":"A novel CD71 Centyrin:Gys1 siRNA conjugate reduces glycogen synthesis and glycogen levels in a mouse model of Pompe disease","volume":"33","author":"Holt","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejmech.2025.118500_bib24","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2320257121","article-title":"A PIKfyve modulator combined with an integrated stress response inhibitor to treat lysosomal storage diseases","volume":"121","author":"Hou","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2025.118500_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202300641","article-title":"Gaucher disease: a glance from a medicinal chemistry perspective","volume":"19","author":"Prencipe","year":"2024","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.118500_bib26","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/sj.cdd.4402013","article-title":"Altered gene expression in cells from patients with lysosomal storage disorders suggests impairment of the ubiquitin pathway","volume":"14","author":"Bifsha","year":"2007","journal-title":"Cell Death Diff"},{"key":"10.1016\/j.ejmech.2025.118500_bib27","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.15252\/embj.201796697","article-title":"Molecular definitions of autophagy and related processes","volume":"36","author":"Galluzzi","year":"2017","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2025.118500_bib28","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1042\/EBC20170055","article-title":"Dysregulation of autophagy as a common mechanism in lysosomal storage diseases","volume":"61","author":"Lane","year":"2017","journal-title":"Essays Biochem."},{"key":"10.1016\/j.ejmech.2025.118500_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.braindev.2024.10.006","article-title":"Chaperone therapy: stabilization and enhancement of endogenous and exogenous lysosomal enzymes","volume":"47","author":"Suzuki","year":"2025","journal-title":"Brain Develop"},{"key":"10.1016\/j.ejmech.2025.118500_bib30","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nbt1018-913","article-title":"FDA approves Galafold, a triumph for Amicus","volume":"36","author":"Moran","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejmech.2025.118500_bib31","article-title":"Recent therapeutic advancements for Gaucher disease","volume":"8","author":"Pradhan","year":"2025","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ejmech.2025.118500_bib32","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1039\/D4CB00218K","article-title":"Development of selective nanomolar cyclic peptide ligands as GBA1 enzyme stabilisers","volume":"6","author":"Katzy","year":"2025","journal-title":"RSC Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118500_bib33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/ijms26010009","article-title":"Developing allosteric chaperones for GBA1-Associated disorders\u2014an integrated computational and experimental approach","volume":"26","author":"Montpeyo","year":"2025","journal-title":"J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118500_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117529","article-title":"Acetal functionalized iminosugars for targeting \u03b2-glucocerebrosidase modulation","volume":"290","author":"Davighi","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118500_bib35","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2406009121","article-title":"High-throughput screening for small-molecule stabilizers of misfolded glucocerebrosidase in Gaucher disease and Parkinson's disease","volume":"121","author":"Williams","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.ejmech.2025.118500_bib36","doi-asserted-by":"crossref","first-page":"11168","DOI":"10.1021\/acs.jmedchem.4c00702","article-title":"Fragment-Based discovery of a series of allosteric-binding site modulators of \u03b2-glucocerebrosidase","volume":"67","author":"Palmer","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118500_bib37","doi-asserted-by":"crossref","first-page":"6732","DOI":"10.3390\/ijms24076732","article-title":"High-dose ambroxol therapy in type 1 Gaucher disease focusing on patients with poor response to enzyme replacement therapy or substrate reduction therapy","volume":"24","author":"Istaiti","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118500_bib38","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.3390\/molecules25122843","article-title":"Strategy for designing selective lysosomal acid \u03b1-glucosidase inhibitors: binding orientation and influence on selectivity","volume":"25","author":"Kato","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118500_bib39","doi-asserted-by":"crossref","first-page":"9023","DOI":"10.1021\/acs.jmedchem.3c00637","article-title":"Design and pharmacological chaperone effects of N-(4\u2032-phenylbutyl)-DAB derivatives targeting the lipophilic pocket of lysosomal acid \u03b1-glucosidase","volume":"66","author":"Kato","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118500_bib40","doi-asserted-by":"crossref","first-page":"14819","DOI":"10.1021\/jacs.2c05666","article-title":"1,6-epi-Cyclophellitol cyclosulfamidate is a bona fide lysosomal \u03b1-glucosidase stabilizer for the treatment of Pompe disease","volume":"144","author":"Kok","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.118500_bib41","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s12035-019-01820-5","article-title":"Molecular approaches for the treatment of Pompe disease","volume":"57","author":"Bellotti","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejmech.2025.118500_bib42","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s00415-023-12096-0","article-title":"Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I\/II study (ATB200-02)","volume":"271","author":"Byrne","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.ejmech.2025.118500_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1451512","article-title":"Cipaglucosidase alfa plus miglustat: linking mechanism of action to clinical outcomes in late-onset Pompe disease","volume":"15","author":"Byrne","year":"2024","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ejmech.2025.118500_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/srep10903","article-title":"Pharmacological chaperones and coenzyme Q10 treatment improves mutant \u03b2-glucocerebrosidase activity and mitochondrial function in neuronopathic forms of Gaucher disease","volume":"5","author":"de la Mata","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.118500_bib45","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1039\/C6CC01564F","article-title":"Glycomimetic- based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases","volume":"52","author":"S\u00e1nchez-Fern\u00e1ndez","year":"2016","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2025.118500_bib46","doi-asserted-by":"crossref","first-page":"823","DOI":"10.3390\/ph15070823","article-title":"GCase enhancers: a potential therapeutic option for Gaucher disease and other neurological disorders","volume":"15","author":"Mart\u00ednez-Bail\u00e9n","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2025.118500_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115005","article-title":"Discovery of small-molecule protein stabilizers toward exogenous alpha-L-iduronidase to reduce the accumulated heparan sulfate in mucopolysaccharidosis type I cells","volume":"247","author":"Lin","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118500_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/chem.202300982","article-title":"Potent and selective cell-active iminosugar inhibitors of human \u03b1-N-acetylgalactosaminidase (\u03b1-NAGAL)","volume":"29","author":"Ashmus","year":"2023","journal-title":"Chem. Eur J."},{"key":"10.1016\/j.ejmech.2025.118500_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116570","article-title":"Design and synthesis of 6-C-alkyl-DMDP type nanomolar inhibitors of \u03b2-galactosidase and \u03b2-glucosidase based on broussonetine S and related derivatives","volume":"275","author":"Gao","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118500_bib50","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202401104","article-title":"Iminosugar-dihydroazulenes as mutant L444P glucocerebrosidase enhancers","volume":"21","author":"Davighi","year":"2024","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.ejmech.2025.118500_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117031","article-title":"Enantiomeric C-6 fluorinated swainsonine derivatives as highly selective and potent inhibitors of \u03b1-mannosidase and \u03b1-L-rhamnosidase: design, synthesis and structure-activity relationship study","volume":"282","author":"Gao","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118500_bib52","doi-asserted-by":"crossref","first-page":"15428","DOI":"10.1073\/pnas.192582899","article-title":"Chemical chaperones increase the cellular activity of N370S \u03b2-glucosidase: a therapeutic strategy for Gaucher disease","volume":"99","author":"Sawkar","year":"2002","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.ejmech.2025.118500_bib53","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1651-2227.2005.tb02116.x","article-title":"Substrate reduction therapy for lysosomal storage diseases","volume":"94","author":"Cox","year":"2005","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.ejmech.2025.118500_bib54","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.chembiol.2005.09.007","article-title":"Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles","author":"Sawkar","year":"2005","journal-title":"Chem Biol"},{"key":"10.1016\/j.ejmech.2025.118500_bib55","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/sj.mt.6300074","article-title":"Pharmacological enhancement of mutated \u03b1-glucosidase activity in fibroblasts from patients with Pompe disease","volume":"15","author":"Parenti","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejmech.2025.118500_bib56","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3390\/biom15030327","article-title":"From molecular therapies to lysosomal transplantation and targeted drug strategies: present applications, limitations, and future prospects of lysosomal medications","volume":"15","author":"Alhowyan","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejmech.2025.118500_bib57","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.carres.2016.01.006","article-title":"Influence of the configurational pattern of sp2-iminosugar pseudo N-, S-, O- and C-glycosides on their glycoside inhibitory and antitumor properties","volume":"429","author":"S\u00e1nchez-Fern\u00e1ndez","year":"2016","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.ejmech.2025.118500_bib58","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1039\/b906968b","article-title":"Glycosidase inhibition by ring-modified castanospermine analogues: tackling enzyme selectivity by inhibitor tailoring","volume":"7","author":"Aguilar-Moncayo","year":"2009","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2025.118500_bib59","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.ejmech.2015.10.038","article-title":"Efficient stereoselective synthesis of 2-acetamido-1,2-dideoxyallonojirimycin (DAJNAc) and sp2-iminosugar conjugates: novel hexosaminidase inhibitors with discrimination capabilities between the mature and precursor forms of the enzyme","volume":"121","author":"de la Fuente","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118500_bib60","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1039\/a705755e","article-title":"N-Thiocarbonyl azasugars: a new family of carbohydrate mimics with controlled anomeric configuration","author":"Jim\u00e9nez Blanco","year":"1997","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2025.118500_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117060","article-title":"\u03b1-GalCer sp2-iminoglycolipid analogs as CD1d-dependent iNKT modulators: evaluation of their immunotherapeutic potential in murine models of asthma and autoimmune hepatitis","volume":"282","author":"Lai","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118500_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115390","article-title":"Fluoro-labelled sp2-iminoglycolipids with immunomodulatory properties","volume":"255","author":"Padilla-P\u00e9rez","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118500_bib63","article-title":"High mannose oligosaccharide hemimimetics that recapitulate the conformation and binding mode to Concanavalin A, DC-SIGN and langerin","volume":"30","author":"Herrera-Gonz\u00e1lez","year":"2023","journal-title":"Chem. Eur J."},{"key":"10.1016\/j.ejmech.2025.118500_bib64","doi-asserted-by":"crossref","first-page":"12086","DOI":"10.1039\/D2CC04478A","article-title":"Mannobioside biomimetics that trigger DC-SIGN binding selectivity","volume":"58","author":"Herrera-Gonz\u00e1lez","year":"2022","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2025.118500_bib65","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1021\/jacs.1c10504","article-title":"Bicyclic picomolar OGA inhibitors enable chemoproteomic mapping of its endogenous post-translational modifications","volume":"144","author":"Gonz\u00e1lez-Cuesta","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.118500_bib66","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1039\/C9SC06334J","article-title":"Conformational analysis and in vivo assays of an anti-cancer vaccine that features an unnatural antigen based on an sp2-iminosugar fragment","volume":"11","author":"Bermejo","year":"2020","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2025.118500_bib67","doi-asserted-by":"crossref","first-page":"8524","DOI":"10.1021\/acs.jmedchem.0c00908","article-title":"Amplified detection of breast cancer autoantibodies using MUC1-Based Tn antigen mimics","volume":"63","author":"Guill\u00e9n-Poza","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118500_bib68","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1002\/cbic.200900442","article-title":"Chaperone activity of bicyclic nojirimycin analogues for Gaucher mutations in comparison with N-(n-nonyl)-deoxynojirimycin","volume":"10","author":"Luan","year":"2009","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2025.118500_bib69","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/cbic.200900142","article-title":"6-Amino-6-deoxy-5,6-di-N-(N\u2032-octyliminomethylidene)nojirimycin: synthesis, biological evaluation, and crystal structure in complex with acid \u03b2-glucosidase","author":"Brumshtein","year":"2009","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2025.118500_bib70","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1002\/cbic.201000323","article-title":"A fluorescent sp2-Iminosugar with pharmacological chaperone activity for Gaucher disease: synthesis and intracellular distribution studies","volume":"11","author":"Luan","year":"2010","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2025.118500_bib71","doi-asserted-by":"crossref","first-page":"11696","DOI":"10.1002\/anie.201505147","article-title":"pH-Responsive pharmacological chaperones for rescuing mutant glycosidases","volume":"54","author":"Mena-Barrag\u00e1n","year":"2015","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2025.118500_bib72","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1021\/acs.jmedchem.6b01550","article-title":"Fluorinated chaperone\u2212\u03b2-cyclodextrin formulations for \u03b2-glucocerebrosidase activity enhancement in neuronopathic Gaucher disease","volume":"60","author":"Garc\u00eda-Moreno","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118500_bib73","doi-asserted-by":"crossref","first-page":"5832","DOI":"10.1021\/acs.jmedchem.9b00153","article-title":"Pharmacological chaperones for the treatment of \u03b1-mannosidosis","author":"R\u00edsquez-Cuadro","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118500_bib74","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1080\/14756366.2022.2073444","article-title":"sp2-Iminosugars targeting human lysosomal \u03b2-hexosaminidase as pharmacological chaperone candidates for late-onset Tay-Sachs disease","volume":"37","author":"Gonz\u00e1lez-Cuesta","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118500_bib75","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/cbic.201200708","article-title":"Bicyclic derivatives of L-idonojirimycin as pharmacological chaperones for neuronopathic forms of Gaucher disease","volume":"14","author":"Alfonso","year":"2013","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2025.118500_bib76","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/hmg\/dds471","article-title":"Neuronopathic Gaucher's disease: induced pluripotent stem cells for disease modelling and testing chaperone activity of small compounds","volume":"22","author":"Tiscornia","year":"2013","journal-title":"Human Mol. Genet."},{"key":"10.1016\/j.ejmech.2025.118500_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107555","article-title":"sp2-Iminosugar azobenzene O-glycosides: light-sensitive glycosidase inhibitors with unprecedented tunability and switching factors","volume":"150","author":"Rivero-Barbarroja","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118500_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108575","article-title":"Light-responsive glycosidase inhibitors: tuning enzyme selectivity and switching factors through integrated chemical and optoglycomic strategies","volume":"162","author":"Rivero-Barbarroja","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118500_bib79","doi-asserted-by":"crossref","first-page":"6514","DOI":"10.1039\/c2cc32065g","article-title":"Tuning glycosidase inhibition through aglycone interactions: pharmacological chaperones for Fabry disease and GM1 gangliosidosis","volume":"48","author":"Aguilar-Moncayo","year":"2012","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2025.118500_bib80","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/mt.2012.263","article-title":"A bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis","volume":"21","author":"Takai","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejmech.2025.118500_bib81","doi-asserted-by":"crossref","first-page":"14560","DOI":"10.1074\/jbc.M113.529529","article-title":"Structural basis of pharmacological chaperoning for human \u03b2-galactosidase","volume":"289","author":"Suzuki","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118500_bib82","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1021\/cb500143h","article-title":"Molecular basis of 1-deoxygalactonojirimycin arylthiourea binding to human \u03b1-galactosidase A: pharmacological chaperoning efficacy on Fabry disease mutants","volume":"9","author":"Yu","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118500_bib83","doi-asserted-by":"crossref","first-page":"927","DOI":"10.3390\/molecules23040927","article-title":"Probing the inhibitor versus chaperone properties of sp2-iminosugars towards human \u03b2-glucocerebrosidase: a picomolar chaperone for Gaucher disease","volume":"23","author":"Mena-Barrag\u00e1n","year":"2018","journal-title":"Molecules"},{"issue":"18","key":"10.1016\/j.ejmech.2025.118500_bib84","doi-asserted-by":"crossref","first-page":"19269","DOI":"10.1021\/acs.jmedchem.5c01349","article-title":"C-Branched iminosugars as selective pharmacological chaperones of lysosomal \u03b1-glucosidase for the treatment of Pompe disease","volume":"68","author":"Vieira Da Cruz","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118500_bib85","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s42004-024-01164-9","article-title":"A practical synthesis of nitrone-derived C5a-functionalized isofagomines as protein stabilizers to treat Gaucher disease","volume":"7","author":"Li","year":"2024","journal-title":"Commun. Chem."},{"key":"10.1016\/j.ejmech.2025.118500_bib86b","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1042\/bj3210557","article-title":"Nomenclature for sugar-binding subsites in glycosyl hydrolases","volume":"321","author":"Davies","year":"1997","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2025.118500_bib86a","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1039\/D5CB00045A","article-title":"dual-functional substrate for quantitation of substrate levels and GCase activity in living cells","volume":"6","author":"Tiet","year":"2025","journal-title":"RSC Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118500_bib87","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202309306","article-title":"A fixable fluorescence-quenched substrate for quantitation of lysosomal glucocerebrosidase activity in both live and fixed cells","volume":"62","author":"Zhu","year":"2023","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2025.118500_bib88","doi-asserted-by":"crossref","DOI":"10.1038\/s41589-021-00960-x","article-title":"Quantifying lysosomal glycosidase activity within cells using bis-acetal substrates","volume":"18","author":"Cecioni","year":"2022","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118500_bib89","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/nyas.13052","article-title":"Disease models for the development of therapies for lysosomal storage diseases","volume":"1371","author":"Xu","year":"2016","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejmech.2025.118500_bib90","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3389\/fmolb.2020.00224","article-title":"Human iPSC-based models for the development of therapeutics targeting neurodegenerative lysosomal storage diseases","volume":"7","author":"Luciani","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.ejmech.2025.118500_bib91","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2025.2468859","article-title":"A stable GH31 \u03b1-glucosidase as a model system for the study of mutations leading to human glycogen storage disease type II","volume":"40","author":"Iacono","year":"2025","journal-title":"J. Enzyme. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118500_bib92","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.3390\/biom13081227","article-title":"Therapeutic role of pharmacological chaperones in lysosomal storage disorders: a review of the evidence and informed approach to reclassification","volume":"13","author":"Keyzor","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejmech.2025.118500_bib93","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3390\/genes16080915","article-title":"Genetic insights and diagnostic challenges in highly attenuated lysosomal storage disorders","volume":"16","author":"Urizar","year":"2025","journal-title":"Genes"},{"key":"10.1016\/j.ejmech.2025.118500_bib94","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3390\/biom14050573","article-title":"Failure of autophagy in Pompe disease","volume":"14","author":"Do","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejmech.2025.118500_bib95","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1093\/brain\/awae070","article-title":"The lysosomal \u03b2-glucocerebrosidase strikes mitochondria: implications for Parkinson's therapeutics","volume":"147","author":"Rubilar","year":"2024","journal-title":"Brain"},{"key":"10.1016\/j.ejmech.2025.118500_bib96","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/s42003-025-08684-7","article-title":"Glucosylsphingosine affects mitochondrial function in a neuronal cell model","volume":"8","author":"Nikolaenko","year":"2025","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ejmech.2025.118500_bib97","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.3390\/genes16111269","article-title":"Secondary mitochondrial dysfunction in Gaucher disease type I, II and III\u2014Review of the experimental and clinical evidence","volume":"16","author":"Dewsbury","year":"2025","journal-title":"Genes"},{"key":"10.1016\/j.ejmech.2025.118500_bib98","doi-asserted-by":"crossref","first-page":"29052","DOI":"10.1074\/jbc.M705005200","article-title":"Crystal structures of complexes of N-butyl- and N-nonyl-deoxynojirimycin bound to acid \u03b2-glucosidase: insights into the mechanism of chemical chaperone action in Gaucher disease","volume":"282","author":"Brumshtein","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118500_bib99","doi-asserted-by":"crossref","DOI":"10.4061\/2011\/973231","article-title":"Enzyme res. A guided tour of the structural biology of Gaucher disease: acid-\u03b2-glucosidase and saposin C","volume":"2011","author":"Lieberman","year":"2011","journal-title":"Enzyme Res"},{"key":"10.1016\/j.ejmech.2025.118500_bib100","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/s41467-017-01263-3","article-title":"Structure of human lysosomal acid \u03b1-glucosidase\u2013a guide for the treatment of Pompe disease","volume":"8","author":"Roig-Zamboni","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118500_bib101","doi-asserted-by":"crossref","first-page":"9136","DOI":"10.1039\/D3SC01021J","article-title":"Fluorescence polarisation activity-based protein profiling for the identification of deoxynojirimycin-type inhibitors selective for lysosomal retaining alpha- and beta-glucosidases","volume":"14","author":"van der Gracht","year":"2023","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2025.118500_bib102","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.ejmech.2015.08.038","article-title":"Inhibitor versus chaperone behaviour of D-fagomine, DAB and LAB sp2-iminosugar conjugates against glycosidases: a structure\u2013activity relationship study in Gaucher fibroblasts","volume":"121","author":"Mena-Barrag\u00e1n","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118500_bib103","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/anie.201003707","article-title":"\u201cClicking\u201d polymers or just efficient linking: what is the difference?","volume":"50","author":"Barner-Kowollik","year":"2011","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2025.118500_bib104","doi-asserted-by":"crossref","first-page":"6210","DOI":"10.1021\/acsomega.1c06718","article-title":"N-Naphthoyl thiourea derivatives: an efficient ultrasonic-assisted synthesis, reaction, and in vitro anticancer evaluations","volume":"7","author":"Arafa","year":"2022","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2025.118500_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2024.122776","article-title":"\u03b2-Cyclodextrin-based geometrically frustrated amphiphiles as one-component, cell-specific and organ-specific nucleic acid delivery systems","volume":"347","author":"Rivero-Barbarroja","year":"2025","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejmech.2025.118500_bib106","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/glycob\/7.2.277","article-title":"Active-site motifs of lysosomal acid hydrolases: invariant features of clan GH-A glycosyl hydrolases deduced from hydrophobic cluster analysis","volume":"7","author":"Durand","year":"1997","journal-title":"Glycobiology"},{"key":"10.1016\/j.ejmech.2025.118500_bib107","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.4161\/auto.6.8.13378","article-title":"Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder-murine Pompe disease","volume":"6","author":"Raben","year":"2010","journal-title":"Autophagy"},{"key":"10.1016\/j.ejmech.2025.118500_bib108","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1194\/jlr.R086629","article-title":"Distinguishing the differences in \u03b2-glycosylceramidase folds, dynamics, and actions informs therapeutic uses","volume":"59","author":"Bdira","year":"2018","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ejmech.2025.118500_bib109","doi-asserted-by":"crossref","first-page":"26052","DOI":"10.1074\/jbc.M113.463562","article-title":"\u03b2-Glucosidase 2 (GBA2) activity and imino sugar pharmacology","volume":"288","author":"Ridley","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118500_bib110","doi-asserted-by":"crossref","first-page":"8362","DOI":"10.1016\/S0021-9258(17)37202-2","article-title":"N-Butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis","volume":"269","author":"Platt","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118500_bib111","doi-asserted-by":"crossref","first-page":"12529","DOI":"10.1002\/anie.201207771","article-title":"Novel activity-based probes for broad-spectrum profiling of retaining \u03b2-exoglucosidases in situ and in vivo","volume":"51","author":"Kallemeijn","year":"2012","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2025.118500_bib112","doi-asserted-by":"crossref","first-page":"16377","DOI":"10.1002\/chem.202102359","article-title":"synthesis and structural analysis of glucocerebrosidase imaging agents","volume":"27","author":"Rowland","year":"2021","journal-title":"Chem. Eur J."},{"key":"10.1016\/j.ejmech.2025.118500_bib113","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1002\/cbic.202100396","article-title":"Xylose-Configured cyclophellitols as selective inhibitors for glucocerebrosidase","volume":"22","author":"Su","year":"2021","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2025.118500_bib114","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cbpa.2019.05.030","article-title":"An overview of activity-based probes for glycosidases","volume":"53","author":"Wu","year":"2019","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118500_bib115","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1021\/acschembio.9b01044","article-title":"Selective fluorogenic \u03b2-glucocerebrosidase substrates for convenient analysis of enzyme activity in cell and tissue homogenates","volume":"15","author":"Deen","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118500_bib116","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1002\/1873-3468.14448","article-title":"In situ glucosylceramide synthesis and its pharmacological inhibition analysed in cells by 13C5-sphingosine precursor feeding and mass spectrometry","volume":"596","author":"Katzy","year":"2022","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejmech.2025.118500_bib117","doi-asserted-by":"crossref","DOI":"10.1021\/acs.analchem.4c02654","article-title":"Evaluation of a liquid chromatography\u2013tandem mass spectrometry method for the analysis of glucosylceramide and galactosylceramide isoforms in cerebrospinal fluid of Parkinson\u2019s disease patients","volume":"96","author":"Castillo-Ribelles","year":"2024","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ejmech.2025.118500_bib118","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-1-59745-157-4_4","article-title":"LC3 and autophagy","volume":"445","author":"Tanida","year":"2008","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.118500_bib119","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.3390\/cells14131016","article-title":"Post-Translational modification of p62: roles and regulations in autophagy","volume":"14","author":"Xiao","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2025.118500_bib120","doi-asserted-by":"crossref","first-page":"35283","DOI":"10.1074\/jbc.M111.267930","article-title":"Lysosomal storage causes cellular dysfunction in mucolipidosis II skin fibroblasts","volume":"286","author":"Otomo","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118500_bib121","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.bbrc.2007.12.187","article-title":"Enhanced autophagy and mitochondrial aberrations in murine GM1-gangliosidosis","volume":"367","author":"Takamura","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2025.118500_bib122","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/s41467-021-22111-5","article-title":"Molecular basis of V-ATPase inhibition by bafilomycin A1","volume":"12","author":"Wang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118500_bib123","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/humu.21121","article-title":"The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase","volume":"30","author":"Flanagan","year":"2009","journal-title":"Human Mut"},{"key":"10.1016\/j.ejmech.2025.118500_bib124","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s10545-017-0048-0","article-title":"Linking mitochondrial dysfunction to neurodegeneration in lysosomal storage diseases","volume":"40","author":"Saffari","year":"2017","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ejmech.2025.118500_bib127","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1089\/gte.1997.1.5","article-title":"Gaucher disease: gene frequencies and genotype\/phenotype correlations","volume":"1","author":"Grabowski","year":"1997","journal-title":"Genet. Test."},{"key":"10.1016\/j.ejmech.2025.118500_bib125","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.neuropharm.2008.06.012","article-title":"[3H]A-804598 ([3H]2-cyano-1-[(1S)1-phenylethyl]3-quinolin-5-yl-guanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors","volume":"56","author":"Donnelly-Roberts","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2025.118500_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.tetlet.2021.152868","article-title":"4-Dimethylaminopyridine-catalyzed synthesis of isothiocyanates from amines and carbon disulfide","volume":"68","author":"Rong","year":"2021","journal-title":"Tetrahedron Lett."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425012656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425012656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:01:23Z","timestamp":1773921683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425012656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":128,"alternative-id":["S0223523425012656"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118500","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neutral sp2-iminosugars exploiting non-glycone interactions for selective acid \u03b1- and \u03b2-glucosidase activity modulation: Pharmacological chaperones for Gaucher and Pompe diseases","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118500","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118500"}}